Business
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial
BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKE™ first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). Patient 10 will be dosed at 100mcg/kg/day.\n\n \n \n \n \n \n \n\n \nHighlights from the first nine patients treated with GTB-3550 TriKE™ include:\nUp to 63.7% Reduction in Bone Marrow Blast Levels Restores Patient's Endogenous NK Cell Function, Proliferation and Immune Surveillance No Progenitor-derived or Autologous/Allogenic Cell Therapy Required No Cytokine Release Syndrome Observed 3 out of the Last 5 Patients Treated (25mcg/kg/day to 100mcg/kg/day) Respond\"We are pleased with the continued clinical performance of our lead TriKE™ product candidate, and in reaching this important patient enrollment milestone,\" said Anthony J. Cataldo, GT Biopharma's Chairman and Chief Executive Officer. \"The data from the first nine patients treated with GTB-3550 indicates significant bone marrow blast level reductions in AML and MDS patients without the need for expensive progenitor-derived or autologous/allogenic cell therapies.\" \nAbout High-Risk Myelodysplastic SyndromesMDS is a rare form of bone marrow-related cancer caused by irregular blood cell production within the bone marrow. As a result of this irregular production, MDS patients do not have sufficient normal red blood cells, white blood cells and/or platelets in circulation. High-risk MDS is associated with poor prognosis, diminished quality of life, and a higher chance of transformation to acute myeloid leukemia. Approximately 40% of patients with High-Risk MDS transform to AML, another aggressive cancer with poor outcomes.\nAbout Acute Myeloid LeukemiaAcute myeloid leukemia is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. According to the National Cancer Institute (NCI), the five-year survival rate is about 35% in people under 60 years old, and 10% in people over 60 years old. Older people whose...